Neoadjuvant Therapy, Pancreatic Cancer, Pathological Complete Response
Conditions
Keywords
CAP grade, tumor response grading system
Brief summary
1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2. Among various pathological tumor regression grading systems, the College of American Pathologists (CAP) system is commonly used to predict chemo-responsiveness and survival. 3. This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response.
Interventions
DRUGneoadjuvant therapy
Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (aged >18 years) who underwent pancreatic resection after NAT at a single center between January 2009 and December 2023. * Patients were initiated on NAT after confirming PDAC diagnosis based on pathological examination.
Exclusion criteria
* Patients without a reported CAP grade * Patients who underwent palliative surgery * Patients who received NAT outside the specified protocol due to incomplete information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 5-year overall survival | assessed up to 60months | from diagnosis to any cause of death |
| 5-year disease-free survival | assessed up to 60months | defined as the duration between the date of surgery and the occurrence of the first instance of recurrence, death, or the last follow-up date. |
Outcome results
None listed